VRTX has 36-month beta value of 0.40. Analysts have mixed views on the stock, with 17 analysts rating it as a “buy,” 5 as “overweight,” 11 as “hold,” and 2 as “sell.”
The public float for VRTX is 256.90M, and currently, short sellers hold a 1.37% ratio of that float. The average trading volume of VRTX on January 10, 2025 was 1.46M shares.
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX)’s stock price has increased by 0.93 compared to its previous closing price of 408.32. However, the company has seen a 2.34% increase in its stock price over the last five trading sessions. accesswire.com reported 2025-01-09 that NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated (“Vertex Pharmaceuticals”) (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
VRTX’s Market Performance
VRTX’s stock has risen by 2.34% in the past week, with a monthly drop of -10.82% and a quarterly drop of -10.20%. The volatility ratio for the week is 1.60% while the volatility levels for the last 30 days are 2.43% for Vertex Pharmaceuticals, Inc The simple moving average for the last 20 days is -3.20% for VRTX stock, with a simple moving average of -9.88% for the last 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with H.C. Wainwright repeating the rating for VRTX by listing it as a “Buy.” The predicted price for VRTX in the upcoming period, according to H.C. Wainwright is $535 based on the research report published on December 20, 2024 of the previous year 2024.
Jefferies gave a rating of “Buy” to VRTX, setting the target price at $550 in the report published on December 09th of the previous year.
VRTX Trading at -9.29% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.73% of loss for the given period.
Volatility was left at 2.43%, however, over the last 30 days, the volatility rate increased by 1.60%, as shares sank -13.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.73% lower at present.
During the last 5 trading sessions, VRTX rose by +2.34%, which changed the moving average for the period of 200-days by -0.85% in comparison to the 20-day moving average, which settled at $425.74. In addition, Vertex Pharmaceuticals, Inc saw 2.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from ALTSHULER DAVID, who sale 15 shares at the price of $478.56 back on Nov 15 ’24. After this action, ALTSHULER DAVID now owns 25,813 shares of Vertex Pharmaceuticals, Inc, valued at $7,178 using the latest closing price.
ALTSHULER DAVID, the Officer of Vertex Pharmaceuticals, Inc, proposed sale 15 shares at $478.56 during a trade that took place back on Nov 15 ’24, which means that ALTSHULER DAVID is holding shares at $7,178 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -2.99, with -2.18 for asset returns.
Currently, EBITDA for the company is 4.61 billion with net debt to EBITDA at -6.83. When we switch over and look at the enterprise to sales, we see a ratio of 9.67. The receivables turnover for the company is 6.06for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.47.
Conclusion
To put it simply, Vertex Pharmaceuticals, Inc (VRTX) has had a mixed performance in recent times. Analysts have a bearish opinion on the stock, with some rating it as a “sell” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
